Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “insulin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 62
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 62 pipeline programs matching "insulin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

62 results for “insulin” Back to intelligence hub

Search results

Page 1 of 3
  1. Alogliptin and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  2. CSII (Insulin Pump) plus DAFNE

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 3 other completed

    1 trial
  3. Dapagliflozin 10 mg

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

    phase 3 small molecule completed

    1 trial
  4. Dasiglucagon 4 mg/ml

    Zealand Pharma A/S

    Children with congenital hyperinsulinism

    phase 3 small molecule active

    1 trial
  5. Faster-acting insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial
  6. G-Pen

    Universal Integrated

    Insulin Hypoglycemia

    phase 3 small molecule completed

    1 trial
  7. G-Pen

    Xeris Biopharma Holdings

    Insulin Hypoglycemia

    phase 3 small molecule completed

    1 trial
  8. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  9. Inhaled Human Insulin

    Nektar Therapeutics UK Limited

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  10. Insulin Degludec and Insulin Aspart

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes

    phase 3 small molecule completed

    1 trial
  11. Insulin degludec/insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial
  12. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  13. Insulin icodec

    Novo Nordisk A/S

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial
  14. Metformin on top of intensive insulin therapy

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  15. TAK-559 and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial
  16. VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial
  17. albiglutide + insulin glargine

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 mab completed

    1 trial
  18. biphasic insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial
  19. insulin degludec

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    2 trials
  20. Glucagon

    Xeris Biopharma Holdings

    Congenital Hyperinsulinism

    phase 2 small molecule completed

    1 trial
  21. Glucagon RTU

    Xeris Biopharma Holdings

    Hyperinsulinemic Hypoglycemia

    phase 2 small molecule completed

    1 trial
  22. Glucagon RTU Injection With Insulin Pump Reduction

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial
  23. HM-GCG-201

    Alphapharm Pty Ltd

    Congenital Hyperinsulinism (CHI)

    phase 2 other active

    1 trial
  24. Insulin

    United Therapeutics Europe Ltd

    Multiple Sclerosis, Relapsing-Remitting

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.